Evidence map›Paper›PMID 38816616›Full record

ArticleNature immunology2024

Affinity gaps among B cells in germinal centers drive the selection of MPER precursors.

Rashmi Ray, Torben Schiffner, Xuesong Wang, Yu Yan, Kimmo Rantalainen, Chang-Chun David Lee, Shivang Parikh, Raphael A Reyes, Gordon A Dale, Ying-Cing Lin and 22 more

Abstract read
In one paragraph

Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Modeling the Synergetic Dynamics of B cells and TbioRxiv : the preprint server for biology · 2025
    Article
  11. Article
  12. Antibody feedback establishes an affinity brake in the germinal center.bioRxiv : the preprint server for biology · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Rashmi Ray *The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Torben Schiffner *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Xuesong Wang *The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Yu Yan *The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Kimmo RantalainenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3158-9183
Chang-Chun David LeeIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
Shivang ParikhThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6364-9307
Raphael A ReyesThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2234-4758
Gordon A DaleThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Ying-Cing LinThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3534-7974
Simone PecettaThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9898-4324
Sophie GiguereThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7961-829X
Olivia SwansonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8162-8358
Sven KratochvilThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0446-2371
Eleonora MelziThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1520-735X
Ivy PhungCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7283-4766
Lisa MadungweThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Oleksandr KalyuzhniyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5273-1951
John WarnerThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Stephanie R WeldonThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Ryan TingleDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Edward LampertiThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Kathrin H KirschThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Nicole PhelpsDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Erik GeorgesonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5137-4625
Yumiko AdachiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Michael KubitzDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Usha NairThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Shane CrottyCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6484-6262
Ian A WilsonIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6469-2419
William R SchiefThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. schief@scripps.edu.ORCID http://orcid.org/0000-0002-1120-0150
Facundo D BatistaThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. fbatista1@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-1130-9463

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIVR01AI147826 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHIFFNER, TORBEN · 2019 to 2025
$8.0M
Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV009585Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV046626Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1147787Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1196345Gates Foundation INV-008813Gates Foundation INV-009585Gates Foundation INV-034657NIAID NIH HHS R01 AI147826NIAID NIH HHS UM1 AI144462U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1 AI44462
6 · The paper itself

Abstract

Current prophylactic human immunodeficiency virus 1 (HIV-1) vaccine research aims to elicit broadly neutralizing antibodies (bnAbs). Membrane-proximal external region (MPER)-targeting bnAbs, such as 10E8, provide exceptionally broad neutralization, but some are autoreactive. Here, we generated humanized B cell antigen receptor knock-in mouse models to test whether a series of germline-targeting immunogens could drive MPER-specific precursors toward bnAbs. We found that recruitment of 10E8 precursors to germinal centers (GCs) required a minimum affinity for germline-targeting immunogens, but the GC residency of MPER precursors was brief due to displacement by higher-affinity endogenous B cell competitors. Higher-affinity germline-targeting immunogens extended the GC residency of MPER precursors, but robust long-term GC residency and maturation were only observed for MPER-HuGL18, an MPER precursor clonotype able to close the affinity gap with endogenous B cell competitors in the GC. Thus, germline-targeting immunogens could induce MPER-targeting antibodies, and B cell residency in the GC may be regulated by a precursor-competitor affinity gap.

Indexed as

Antibody AffinityB-LymphocytesGerminal CenterHIV-1HIV AntibodiesAIDS VaccinesAnimalsAntibodies, NeutralizingBroadly Neutralizing AntibodiesGene Knock-In TechniquesHIV InfectionsHumansMiceMice, Inbred C57BLMice, TransgenicReceptors, Antigen, B-CellAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesReceptors, Antigen, B-Cell

Identifiers

PMID38816616
PMCPMC11147770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.